TRK Inhibitors: Clinical Development of Larotrectinib

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Mutational Burden Guides Therapy in a Treatment RefractoryPOLE‐Mutant Uterine Carcinosarcoma

(2018) Munveer S. Bhangoo et al.   ONCOLOGIST

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors

(2018) Dazhi Liu et al.   Therapeutics and Clinical Risk Management

Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma

(2018) David S. Ziegler et al.   BRITISH JOURNAL OF CANCER

Comprehensive detection of targetable fusions in lung adenocarcinomas by complementary targeted DNAseq and RNAseq assays.

(2018) Ryma Benayed et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions

(2017) D.S. Hong et al.   EUROPEAN JOURNAL OF CANCER

The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

(2017) David Michael Hyman et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of Entrectinib in a Patient With the First Reported NTRK Fusion in Neuroendocrine Cancer

(2017) Darren Sigal et al.   Journal of the National Comprehensive Cancer Network

Targeting TRK family proteins in cancer

(2017) Yekaterina B. Khotskaya et al.   PHARMACOLOGY & THERAPEUTICS

A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion–Positive Solid Tumors

(2017) Alexander Drilon et al.   Cancer Discovery

Abstract 2954A: A potent and selective TRK inhibitor ONO-5390556, shows potent antitumor activity against both TRK-rearranged cancers and the resistant mutants

(2016) Ryohei Kozaki et al.   CANCER RESEARCH

Infantile Fibrosarcoma WithNTRK3-ETV6Fusion Successfully Treated With the Tropomyosin-Related Kinase Inhibitor LOXO-101

(2016) Ramamoorthy Nagasubramanian et al.   PEDIATRIC BLOOD & CANCER

Abstract 4529: Pharmacokinetics (PK) of LOXO-101 during the first-in-human Phase I study in patients with advanced solid tumors: Interim update

(2015) Howard A. Burris et al.   CANCER RESEARCH

Abstract PR13: Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions

(2015) David S. Hong et al.   MOLECULAR CANCER THERAPEUTICS

An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101

(2015) R. C. Doebele et al.   Cancer Discovery

Functional characterization ofNTRK1mutations identified in melanoma

(2015) Claudia Miranda et al.   GENES CHROMOSOMES & CANCER

TRKing Down an Old Oncogene in a New Era of Targeted Therapy

(2014) Aria Vaishnavi et al.   Cancer Discovery

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

(2013) Aria Vaishnavi et al.   NATURE MEDICINE

Brain-Derived Neurotrophic Factor/Tyrosine Kinase B Signaling Regulates Human Trophoblast Growth in anin VivoAnimal Model of Ectopic Pregnancy

(2011) Kazuhiro Kawamura et al.   ENDOCRINOLOGY

Brain-Derived Neurotrophic Factor Promotes Implantation and Subsequent Placental Development by Stimulating Trophoblast Cell Growth and Survival

(2009) Kazuhiro Kawamura et al.   ENDOCRINOLOGY

Rearrangements of NTRK1 gene in papillary thyroid carcinoma

(2009) A. Greco et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY